T
Timothy J. Perren
Researcher at St James's University Hospital
Publications - 163
Citations - 11923
Timothy J. Perren is an academic researcher from St James's University Hospital. The author has contributed to research in topics: Breast cancer & Ovarian cancer. The author has an hindex of 52, co-authored 158 publications receiving 10331 citations. Previous affiliations of Timothy J. Perren include Leeds General Infirmary & University of Birmingham.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe,Jane Hook,Matthew Nankivell,Gordon C Jayson,Henry C Kitchener,Tito Lopes,David Luesley,Timothy J. Perren,Selina Bannoo,Monica Mascarenhas,Stephen Dobbs,Sharadah Essapen,Jeremy Twigg,Jonathan Herod,Glenn McCluggage,Mahesh K.B. Parmar,Ann Marie Swart,Ann Marie Swart +17 more
TL;DR: In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery, and giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.
Journal ArticleDOI
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M. Oza,Adrian Cook,Jacobus Pfisterer,Andrew C. Embleton,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Tjoung Won Park-Simon,Gordon J. S. Rustin,Florence Joly,Mansoor Raza Mirza,Marie Plante,Michael A. Quinn,Andres Poveda,Gordon C Jayson,Dan Stark,Ann Marie Swart,Laura Farrelly,Richard Kaplan,Mahesh K. B. Parmar,Timothy J. Perren +23 more
TL;DR: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression, so evidence of non-proportional hazards was shown.
Journal ArticleDOI
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter,Marion Procter,Dirk J. van Veldhuisen,M. Muscholl,Jonas Bergh,Chiara Carlomagno,Timothy J. Perren,Rodolfo Passalacqua,Claudia Bighin,Jan G. M. Klijn,Fail T. Ageev,Erika Hitre,Juergen Groetz,Hiroji Iwata,Malgorzata Knap,Michael Gnant,S. Muehlbauer,Alison Spence,Richard D. Gelber,Martine Piccart-Gebhart +19 more
TL;DR: Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.
Journal ArticleDOI
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial
M. K. B. Parmar,M. Adams,M. Balestrino,K. Bertelsen,C. Bonazzi,H.T. Calvert,Nicoletta Colombo,J. F. Delaloye,A. Durando,David Guthrie,B. Hagen,P. Harper,C. Mangioni,Timothy J. Perren,Christopher J. Poole,Wendi Qian,Gordon J. S. Rustin,J. Sandercock,S. Tumolo,Valter Torri,F. Vecchione,A. Tinazzi,B. M. Uscinska,S. Collins,M.A. Flann,A. Buda,B. Taylor,I. Tannock,R. Souhami,M. Grazia-Valsecchi +29 more
TL;DR: The favourable toxicity profile of single-agent carboplatin suggests that this drug is a reasonable option as first-line chemo therapy for ovarian cancer.